34th Piper Sandler Annual Healthcare Conference and RBC Capital Markets Healthcare Private Company Virtual Conference
MONTREAL, Quebec, Canada | November 17, 2022
Thryv Therapeutics Inc., a biopharmaceutical company focused on a precision medicine approach to treat Long QT Syndromes via SGK1 inhibition and resistant cancers, will participate in a fireside chat and host investor meetings at the upcoming 34th Piper Sandler Annual Healthcare Conference, and will participate in a fireside chat at the upcoming 2022 RBC Capital Markets Healthcare Private Company Conference.
Mr. Paul F. Truex will provide a full update on Thryv’s progress to date with the development of a number of highly potent SGK1 inhibitors for all major forms of Long QT Syndrome, atrial fibrillation and resistant cancers.
Piper Sandler 34th Annual Healthcare Conference
Location: New York, NY
Fireside Chat: Tuesday, November 29th, 2022 at 11:10 a.m. ET
1x1 Meetings: Tuesday, November 29th, 2022
RBC Capital Markets Healthcare Private Company Virtual Conference
Virtual Fireside Chat: Wednesday, December 14th, 2022
About Thryv Therapeutics Inc.
Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned pharmaceutical company pioneering a precision medicine approach through the inhibition of Serum and Glucocorticoid induced Kinase (SGK1) to treat Long QT Syndrome, Atrial Fibrillation, and resistant and rare cancers.
Media Inquiries
Contact daphne@thryvtrx.com | 514 973 0915
